Expertise in
4
conditions

Seong-eun K. Kim

Seoul, KR 
Expertise in
4
conditions
Seoul, KR 
OverviewLocationsClinical Research

Overview

Seong-eun Kim practices in Seoul, Republic of Korea. Kim is highly rated in 4 conditions, according to our data. Their top areas of expertise are Viral Gastroenteritis, Colitis, Colorectal Cancer, Colonoscopy, and Endoscopy.

Their clinical research consists of co-authoring 137 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Seoul, Republic of Korea
Other Locations
Yangch'on, Republic of Korea
Gwangju, Republic of Korea
Yuhan Care R&D Center, 17084 Republic Of Korea, Yongin, Republic of Korea
Mokdong, Republic of Korea
Convergence System R&D Division, 25 Saenari Ro, Seongnam Si 13509, Songnam, Republic of Korea
Iksan, Republic of Korea
Nung-dong, Republic of Korea
Jeonju, Republic of Korea
Daejeon, Republic of Korea
561756, Republic of Korea
Waegwan, 380701, Republic of Korea
Chungbuk, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
Prospective Randomized Controlled Trial of Cap-Assisted ChromoEndoscopy(CapACE) Versus Conventional Colonoscopy(CC) for the Detection of Colorectal Neoplasia
Prospective Randomized Controlled Trial of Cap-Assisted ChromoEndoscopy(CapACE) Versus Conventional Colonoscopy(CC) for the Detection of Colorectal Neoplasia
Enrollment Status: Completed
Publish Date: December 13, 2018
Intervention Type: Device
Study Phase: Not Applicable
View 2 Less Clinical Trials

137 Total Publications

Cell-derived vesicles extruded from adipose mesenchymal stem cells attenuate intestinal inflammation and augment epithelial regeneration in a colitis model.
Cell-derived vesicles extruded from adipose mesenchymal stem cells attenuate intestinal inflammation and augment epithelial regeneration in a colitis model.
Journal: Nanoscale
Published: November 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Kim's expertise for a condition
ConditionClose
      View All 31 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile